J 2022

Prediction of Sudden Cardiac Arrest After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: ASA-SCARRE Risk Score

VESELKA, Josef, Max LIEBREGTS, Robert COOPER, Lothar FABER, Jaroslav JANUSKA et. al.

Základní údaje

Originální název

Prediction of Sudden Cardiac Arrest After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: ASA-SCARRE Risk Score

Autoři

VESELKA, Josef (203 Česká republika, garant), Max LIEBREGTS, Robert COOPER, Lothar FABER, Jaroslav JANUSKA (203 Česká republika), Maksim KASHTANOV, Klara Hulikova TESARKOVA, Peter Riis HANSEN, Hubert SEGGEWISS, Eugene SHLOYDO, Kirill POPOV, Eva HANSVENCLOVA, Eva POLAKOVA (203 Česká republika), Jurrien Ten BERG, Rodney Hilton STABLES, Jiří JARKOVSKÝ (203 Česká republika, domácí) a Jiri BONAVENTURA (203 Česká republika)

Vydání

American Journal of Cardiology, Bridgewater, Excerpta Medica INC-Elsevier Science INC, 2022, 0002-9149

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.800

Kód RIV

RIV/00216224:14110/22:00128732

Organizační jednotka

Lékařská fakulta

UT WoS

000877775500016

Klíčová slova anglicky

Alcohol Septal Ablation-Sudden Cardiac ARREst; Hypertrophic Obstructive Cardiomyopathy

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 24. 7. 2023 12:57, Mgr. Tereza Miškechová

Anotace

V originále

This study aimed to derive a new score, the Alcohol Septal Ablation-Sudden Cardiac ARREst (ASA-SCARRE) risk score, that can be easily used to evaluate the risk of sudden cardiac arrest events (sudden cardiac death, resuscitation, or appropriate implantable cardioverter-defibrillator discharge) after alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy. We analyzed 1,834 patients from the Euro-ASA registry (49% men, mean age 57 +/- 14 years) who were followed up for 5.0 +/- 4.3 years (9,202 patient-years) after ASA. A total of 65 patients (3.5%) experienced sudden cardiac arrest events, translating to 0.72 events per 100 patient-years. The independent predictors of sudden cardiac arrest events were septum thickness before ASA (hazard ratio 1.09 per 1 mm, 95% confidence interval 1.04 to 1.14, p <0.001) and left ventricular outflow tract (LVOT) gradient at the last clinical checkup (hazard ratio 1.01 per 1 mm Hg, 95% confi-dence interval 1.01 to 1.02, p = 0.002). The following ASA-SCARRE risk scores were derived and independently predicted long-term risk of sudden cardiac arrest events: "0" for both LVOT gradient <30 mmHg and baseline septum thickness <20 mm; "1" for LVOT gradient >= 30 mm Hg or baseline septum thickness >= 20 mm; and "2" for both LVOT gradient >= 30 mm Hg and baseline septum thickness >= 20 mm. The C statistic of the ASA-SCARRE risk score was 0.684 (SE 0.030). In conclusion, the ASA-SCARRE risk score may be a useful and easily available clinical tool to predict risk of sudden cardiac arrest events after ASA in patients with hypertrophic obstructive cardiomyopathy. (c) 2022 Elsevier Inc. All rights reserved. (Am J Cardiol 2022;184:120-126) This study aimed to derive a new score, the Alcohol Septal Ablation-Sudden Cardiac ARREst (ASA-SCARRE) risk score, that can be easily used to evaluate the risk of sudden cardiac arrest events (sudden cardiac death, resuscitation, or appropriate implantable cardioverter-defibrillator discharge) after alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy. We analyzed 1,834 patients from the Euro-ASA registry (49% men, mean age 57 +/- 14 years) who were followed up for 5.0 +/- 4.3 years (9,202 patient-years) after ASA. A total of 65 patients (3.5%) experienced sudden cardiac arrest events, translating to 0.72 events per 100 patient-years. The independent predictors of sudden cardiac arrest events were septum thickness before ASA (hazard ratio 1.09 per 1 mm, 95% confidence interval 1.04 to 1.14, p <0.001) and left ventricular outflow tract (LVOT) gradient at the last clinical checkup (hazard ratio 1.01 per 1 mm Hg, 95% confi-dence interval 1.01 to 1.02, p = 0.002). The following ASA-SCARRE risk scores were derived and independently predicted long-term risk of sudden cardiac arrest events: "0" for both LVOT gradient <30 mmHg and baseline septum thickness <20 mm; "1" for LVOT gradient >= 30 mm Hg or baseline septum thickness >= 20 mm; and "2" for both LVOT gradient >= 30 mm Hg and baseline septum thickness >= 20 mm. The C statistic of the ASA-SCARRE risk score was 0.684 (SE 0.030). In conclusion, the ASA-SCARRE risk score may be a useful and easily available clinical tool to predict risk of sudden cardiac arrest events after ASA in patients with hypertrophic obstructive cardiomyopathy.